A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Must have received: systemic therapy

Must have been previously treated with at least 1 prior systemic therapy followed by relapsed, refractory or progressive disease

Cannot have received: systemic therapy

Prior systemic therapy (eg, chemotherapy, immunomodulatory therapy, or monoclonal antibody therapy) within 3 weeks prior to the first dose of study drug

Cannot have received: lenalidomide (lenalidomide)

Having progressive disease while on prior lenalidomide, discontinuing lenalidomide due to unacceptable toxicity, or prior lenalidomide therapy within the past 12 months prior to the first dose of study drug

Cannot have received: curative radiation therapy

Had curative radiation therapy or major surgery within 4 weeks or palliative radiation therapy within 2 weeks prior to the first dose of study drug

Cannot have received: autologous stem cell transplant

History of autologous stem cell transplant within 60 days prior to first dose of study drug

Cannot have received: allogeneic stem cell transplant

History of allogeneic stem cell transplant within 90 days prior to the first dose of study drug, and clinically significant graft-versus-host disease (GVHD) or GVHD requiring systemic immunosuppressive prophylaxis or treatment

Cannot have received: EZH inhibitor

Prior EZH inhibitor therapy